Survival among women with triple receptor-negative breast cancer and brain metastases.
about
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelTriple receptor-negative breast cancer: imaging and clinical characteristics.Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data.Progress in the biological understanding and management of breast cancer-associated central nervous system metastases.Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment.Circulating tumor cells in non-metastatic triple-negative breast cancer.Minireview: Basal-like breast cancer: from molecular profiles to targeted therapiesTriple-negative breast cancer: new perspectives for targeted therapies.Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey.Triple-negative breast cancer: adjuvant therapeutic options.Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancerPrognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy.Clinicopathological classification and traditional prognostic indicators of breast cancer.Triple negative breast cancer - our experience and reviewTreatment of Breast Cancer Brain Metastases.Update on triple-negative breast cancer: prognosis and management strategiesNovel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.Effect of HER2 status on distant recurrence in early stage breast cancerAn institutional retrospective analysis of 93 patients with brain metastases from breast cancer: treatment outcomes, diagnosis-specific prognostic factors.Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients.Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer NetworkTargeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain MetastasesIncidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer.Triple-negative breast cancer--current status and future directions.Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline.Novel biomarkers of metastatic cancer.The paradox of triple negative breast cancer: novel approaches to treatment.Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study.Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells.[10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo.The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
P2860
Q28728830-2C084755-4A51-40BA-9211-B6EF4C26E063Q30455153-5B08FA80-A8F3-4F67-BC76-50838A6AC7F3Q30557877-77550C2A-0599-4B8D-90AE-B88B2509A8A1Q33777436-843B5C66-20E0-42BC-8FCC-073BA187E9C4Q33878643-78FC8E9C-7AE8-40C4-BA1B-A15BF35DECB8Q33953465-526A6665-D9D7-42CF-B8F1-D0100E50A5B7Q34111867-0FDBAADC-4E00-4869-87CC-C4C0544C78A1Q34562257-E2735B34-4E95-45B9-8ABB-F25CCD25227DQ35001758-35D38642-74F7-4D93-941E-CE2E7B7B8802Q35145663-1937323F-C83B-40D6-A618-72C5380F504AQ35692146-546FFD4E-73EC-4810-B494-1916DD41F760Q35777113-ECD8D8B5-5EFF-4BA9-8BC8-0165A7CA64BFQ35928878-5004F031-9E02-42F7-8750-66C0D75B36D4Q36014485-5363B496-85AB-455A-8C7E-04A38FFB08BAQ36024205-11475BB1-F972-4B1B-894E-91A2110B6442Q36057858-7E8C751E-55C7-49BD-856A-DD8E30706D93Q36311616-8D44111F-32CF-4390-9556-0C2D147137B4Q36343773-F417A39F-91E6-4939-A175-57E0759130CAQ36352501-C4A5A5EC-6141-46BD-9257-C93661AF513DQ36452287-16739789-4E66-4774-AB95-A6B2D68BFE27Q36530791-0D85F3BB-2DF3-4CE8-AAE3-91FC612E28B7Q36538454-174CB39A-DD5C-4846-AEFC-7F61371B67A9Q36651026-459B1696-C924-49DD-AE87-CA607961AD0DQ36726996-503035BB-975B-4CE0-B0FA-13026FB567F6Q36923104-6EE76F07-D0A5-4B62-9776-22499B6705E4Q37122293-71AF5EDE-9B24-4E23-8578-555A0BA693BCQ37398492-8C72E5A4-F7A7-4962-9135-C30C63CA2DD2Q37542524-BB20BC83-821F-4B9F-BD51-3AEFE1F79801Q37630082-157CE826-77FC-41EE-8F84-B6D606F6CBFFQ37698300-B1019C8A-C4FA-4F07-BEDC-A7DCD6330215Q37772496-91F600EB-CBFF-4A46-A745-1104CD1FE02CQ37958063-22071A39-27DB-4263-8D8C-B3CB0135B1AFQ38726649-92735721-7896-4B54-A56E-32CFB9AF8173Q38829087-EB75CF34-53F0-4185-985F-DEAEE305EF23Q38903136-A17B11CE-5087-48A9-8677-82D66674667DQ39007492-970E005A-2502-4643-9CB8-F0DD8A97FBFBQ39192269-765C98F9-EA95-4E6F-BFAB-816A25E525FFQ42700809-EE06262D-5910-43CB-A697-944EB775AF7FQ43375967-EB322861-63BB-4990-B34E-71E26B012915Q43532193-B6FB48CB-D067-4638-A13B-C9B7EA94FE15
P2860
Survival among women with triple receptor-negative breast cancer and brain metastases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Survival among women with triple receptor-negative breast cancer and brain metastases.
@en
Survival among women with triple receptor-negative breast cancer and brain metastases.
@nl
type
label
Survival among women with triple receptor-negative breast cancer and brain metastases.
@en
Survival among women with triple receptor-negative breast cancer and brain metastases.
@nl
prefLabel
Survival among women with triple receptor-negative breast cancer and brain metastases.
@en
Survival among women with triple receptor-negative breast cancer and brain metastases.
@nl
P2093
P2860
P356
P1433
P1476
Survival among women with triple receptor-negative breast cancer and brain metastases.
@en
P2093
A M Gonzalez-Angulo
C Albarracin
F J Esteva
G N Hortobagyi
P2860
P304
P356
10.1093/ANNONC/MDN682
P577
2009-01-15T00:00:00Z